[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb - U.S. Food and Drug Administration Updates CAMZYOS (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications",
    "summary": "PRINCETON, N.J. - Bristol Myers Squibb today announced that the U.S. Food and Drug Administration has updated the U.S. Prescribing Information for CAMZYOS , simplifying treatment for patients and...",
    "url": "https://finnhub.io/api/news?id=f99a641976d32683f83853c80d8f4c9ec2768e47ae1cf733cbb45a4fb071e04e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745236222,
      "headline": "Bristol Myers Squibb - U.S. Food and Drug Administration Updates CAMZYOS (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications",
      "id": 134023547,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "PRINCETON, N.J. - Bristol Myers Squibb today announced that the U.S. Food and Drug Administration has updated the U.S. Prescribing Information for CAMZYOS , simplifying treatment for patients and...",
      "url": "https://finnhub.io/api/news?id=f99a641976d32683f83853c80d8f4c9ec2768e47ae1cf733cbb45a4fb071e04e"
    }
  }
]